



ASX ANNOUNCEMENT

Simavita releases ASX Appendix 4C for the quarter ended June 30, 2017

For Immediate Release:

July 28, 2017

Sydney, Australia – Simavita Limited (“**Simavita**” or the “**Company**”) (ASX: SVA) today reported its 30 June, 2017 quarter results together with financial highlights during the period.

Highlights included:

- **Cash receipts from customers were higher than previous quarters at \$347k and \$1m for the financial year.**
- **Labour costs continue to be reduced with costs for the quarter of \$1.06m down from \$2.34m for the corresponding period in the previous year. Additional redundancies occurred in the quarter which will further reduce labour costs going forward.**
- **Simavita ended the final quarter for the financial year to end 30 June, 2017 with cash reserves of AUD\$2.07 million.**
- **During the quarter the Company successfully raised \$2.0m, net of transaction costs, through a placement of share to sophisticated investors and through a partially underwritten rights issue.**
- **Importantly, existing customers in North American and Australian markets have adopted assessPLUS™, the Company’s latest version of its incontinence assessment tool.**
- **Continued tight management of operating costs with cash outflows for the quarter of \$1.82m down from \$3.31m for the corresponding period in the previous year.**

Michael Spooner, Chairman Simavita Limited said “The Company has continued to focus upon a significant reduction in operating costs. At the same time, management are committed to delivering our Pivot Strategy of rapidly building a highly valuable and profitable business. Key to our strategy is alertPLUS™. Simavita’s completely new platform technology based upon hyper low cost sensor technology for “every day use” in all adult and infant diapers.”

For further information, please view our website (www.simavita.com) or contact:

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com

Forward-Looking Information

This document may contain "forward-looking information" within the meaning of Canadian securities laws ("forward-looking information"). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management's expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or information that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita's interim and annual financial statements and management's discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information

+Rule 4.7B

Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity SIMAVITA LIMITED

ARBN 165 831 309

Quarter ended: 30 June 2017

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (twelve months) \$A'000
1 Cash flows from operating activities		
1.1 Receipts from customers	347	1,002
1.2 Payments for		
(a) research and development	(70)	(274)
(b) product manufacturing and operating costs	(84)	(622)
(c) advertising and marketing	(155)	(708)
(d) leased assets	-	-
(e) staff costs	(1,066)	(5,498)
(f) administration and corporate costs	(453)	(1,742)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	2	20
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	1,660
1.8 Other: GST refund	16	69
1.9 Net cash from / (used in) operating activities	(1,463)	(6,093)
2 Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(3)
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:	-	-
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	(3)
3 Cash flows from financing activities		
3.1 Proceeds from issues of shares	2,188	2,188
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(183)	(183)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-

3.9 Other (provide details if material)

3.1 Net cash from / (used in) financing activities

-	-
2,005	2,005

	Current quarter \$A'000	Year to date (twelve months) \$A'000
4 Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	1,527	6,173
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,463)	(6,093)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	(3)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	2,005	2,005
4.5 Effect of movement in exchange rates on cash held	3	(10)
4.6 Cash and cash equivalents at end of quarter	2,072	2,072

	Current quarter \$A'000	Previous quarter \$A'000
5 Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		
5.1 Bank balances	2,072	1,527
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,072	1,527

	Current quarter \$A'000	
6 Payments to directors of the entity and their associates		
6.1 Aggregate amount of payments to these parties included in item 1.2	75	
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3		
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2		Directors' Fees plus superannuation

	Current quarter \$A'000	
7 Payments to related entities of the entity and their associates		
7.1 Aggregate amount of payments to these parties included in item 1.2	-	
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-	
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2		None

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8 Financing facilities available <i>Add notes as necessary for an understanding of the position</i>		
8.1 Loan facilities	None	None
8.2 Credit standby arrangements	None	None
8.3 Other (please specify)	None	None
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.	None	None

	\$A'000
9 Estimated cash outflows for next quarter	
9.1 Research and development	(120)
9.2 Product manufacturing and operating costs	(100)
9.3 Advertising and marketing	(150)
9.4 Leased assets	-
9.5 Staff costs	(1,000)
9.6 Administration and corporate costs	(430)

9.7 Other (provide details if material)

9.8 Total estimated cash outflows


(1,800)

**10 Acquisitions and disposals of business entities
(items 2.1(b) and 2.2(b) above)**

	Acquisitions	Disposals
10.1 Name of entity	Not applicable	Not applicable
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  Date: 28-Jul-17
Company secretary

Print name: Peta Jurd

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.